title: Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
authors: Ester M
authors: EM
authors: Orlandi
authors: Barbara
authors: B
authors: Rocca
authors: Anna S
authors: AS
authors: Pazzano
authors: Stefano
authors: S
authors: Ghio
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069439:Dasatinib; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects*; D012075:Remission, Spontaneous; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib